218. アルポート症候群 Alport syndrome Clinical trials / Disease details
臨床試験数 : 30 / 薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05448755 (ClinicalTrials.gov) | November 28, 2022 | 29/6/2022 | A Study of ELX-02 in Patients With Alport Syndrome | A Phase 2 Open Label Pilot Study to Evaluate the Safety and Efficacy of Subcutaneously Administered ELX-02 in Patients With Alport Syndrome With Col4A5 and Col4A3/4 Nonsense Mutation | Alport Syndrome | Drug: ELX-02 | Eloxx Pharmaceuticals, Inc. | NULL | Recruiting | 6 Years | 30 Years | All | 8 | Phase 2 | Australia;United Kingdom |